Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint
ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused –– ...
Business Insider8d
Agios Pharmaceuticals reports results from Phase 3 ACTIVATE-Kids study
Agios Pharmaceuticals (AGIO) announced that the ACTIVATE-Kids Phase 3 study of mitapivat in children aged 1 to less than18 years with PK deficiency who are not regularly transfused achieved its ...
WDIO6d
Young Athlete’s Foundation getting kids active with ‘Let’s Move At The Depot’
Saturday the Young Athlete's Association is hosting 'Let's Move At the Depot' a fun family even that provides tons of ...
Nasdaq7d
Agios Pharmaceuticals Announces Positive Phase 3 Results for Mitapivat in Pediatric PK Deficiency Patients
Agios Pharmaceuticals announced positive results from the ACTIVATE-Kids Phase 3 study, the first to demonstrate the efficacy of mitapivat, an oral therapy, for children aged 1 to under 18 with ...
Yahoo Finance6d
Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years
On Thursday, Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced that the ACTIVATE-Kids Phase 3 study of mitapivat in children aged 1 to <18 years with PK deficiency who are not regularly ...
NYC Kids Rise lets public school alumni invest in college scholarships for elementary school students
A unique program allows public school alumni to invest in the future generations of students by contributing to their college scholarships.
Yahoo Finance7d
Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint
In the ACTIVATE-Kids 20-week double-blind treatment period, the safety results were consistent with the safety profile for mitapivat previously observed for adult patients with PK deficiency who ...
Yahoo Finance7d
Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint
Feb. 13, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today ...
Mena FN7d
Agios’ Phase 3 ACTIVATE-Kids Study Of Mitapivat In Children With Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint
(MENAFN- GlobeNewsWire - Nasdaq) – ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused – – Safety ...